Outlook Therapeutics® to Present at Guggenheim’s 5th Annual Inflammation, Neurology & Immunology (INI) Conference
November 01 2023 - 8:05AM
Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical
company working to achieve FDA approval for the first ophthalmic
formulation of bevacizumab for the treatment of retinal diseases,
today announced that Russell Trenary, President and CEO of Outlook
Therapeutics will participate in a fireside chat at Guggenheim’s
5th Annual Inflammation, Neurology & Immunology (INI)
Conference, being held in New York, NY on Tuesday, November 7, 2023
at 1:50 PM ET.
In addition to the fireside chat, management
will be available to participate in in-person one-on-one meetings
with qualified members of the investor community who are registered
to attend the conference.
A live audio webcast of the fireside chat will
be accessible on the Events page in the Investors section of the
Company’s website (outlooktherapeutics.com). A webcast replay will
be archived for 90 days following the event.
About Outlook Therapeutics,
Inc.
Outlook Therapeutics is a biopharmaceutical
company working to achieve FDA approval for the launch of ONS-5010/
LYTENAVA™ (bevacizumab-vikg) as the first FDA-approved ophthalmic
formulation of bevacizumab for use in retinal indications,
including wet AMD, DME and BRVO. The FDA accepted Outlook
Therapeutics’ BLA submission for ONS-5010 to treat wet AMD with an
initial PDUFA goal date of August 29, 2023; FDA did not approve the
BLA during this review cycle and the Company is working with the
FDA to address the issues that have been raised so that the BLA may
be re-submitted. The submission is supported by Outlook
Therapeutics’ wet AMD clinical program, which consists of three
clinical trials: NORSE ONE, NORSE TWO, and NORSE THREE. If ONS-5010
ophthalmic bevacizumab is approved, Outlook Therapeutics expects to
commercialize it as the first and only FDA-approved ophthalmic
formulation of bevacizumab for use in treating retinal diseases in
the United States, United Kingdom, Europe, Japan, and other
markets. As part of the Company’s multi-year commercial planning
process, Outlook Therapeutics and Cencora, formerly
AmerisourceBergen, entered into a strategic commercialization
agreement to expand the Company’s reach for connecting to retina
specialists and their patients. Cencora will provide third-party
logistics (3PL) services and distribution, as well as
pharmacovigilance services and other services in the United States.
For more information, please visit www.outlooktherapeutics.com.
CONTACTS:
Media Inquiries:Harriet UllmanVice
PresidentLaVoieHealthScienceT:
617.429.5475hullman@lavoiehealthscience.com
Investor
Inquiries:
Jenene Thomas Chief Executive Officer JTC Team, LLC T: 833.475.8247
OTLK@jtcir.com
Outlook Therapeutics (NASDAQ:OTLKW)
Historical Stock Chart
From Sep 2024 to Oct 2024
Outlook Therapeutics (NASDAQ:OTLKW)
Historical Stock Chart
From Oct 2023 to Oct 2024